Zhixiang Jintai announced that recently, the company received a “Notice of Acceptance” issued by the State Drug Administration regarding the application for registration and marketing of “GR1803 injection” drugs produced in China. The indications for this application to be approved for marketing are that this product is suitable for adult patients with recurrent or refractory multiple myeloma who have received at least third-line treatment in the past.

Zhitongcaijing · 4d ago
Zhixiang Jintai announced that recently, the company received a “Notice of Acceptance” issued by the State Drug Administration regarding the application for registration and marketing of “GR1803 injection” drugs produced in China. The indications for this application to be approved for marketing are that this product is suitable for adult patients with recurrent or refractory multiple myeloma who have received at least third-line treatment in the past.